International Journal of Molecular Medical Science, 2024, Vol.14, No.1, 61-68 http://medscipublisher.com/index.php/ijmms 67 As genomic information is increasingly used in the medical field, related ethical, privacy and regulatory issues will also receive more attention. We look forward to the continuous improvement of relevant regulations to ensure the safe, legal and compliant use of genomic information and protect patients' rights. Privacy and rights (Blobel et al., 2016). The future development trend of genomic information in optimizing drug treatment and personalized medicine is full of potential and opportunities. With the continuous advancement of technology and the strengthening of interdisciplinary cooperation, it is expected to achieve more accurate, safe and effective personalized medicine in the future, making greater contributions to human health and well-being. 4.3 Put forward suggestions and strategies to promote the development of personalized medicine In order to promote the development of personalized medicine, we must first continue to strengthen the research and development of genomics and related technologies, improve their maturity and promote popularization, so as to ensure that a wider range of patients can benefit from them. It is crucial to establish a sound genomic information database and sharing platform, which will help promote the openness and sharing of data and provide researchers with abundant resources. The training and education of medical personnel cannot be ignored. By improving their knowledge of genomics and personalized medicine, treatment options can be ensured to be more accurate and effective (Lai et al., 2020). Formulating and improving relevant regulations and policies is also the key to ensuring the legality and safety of personalized medicine. It is also necessary to strengthen communication and education with patients, improve their awareness of personalized medicine, and encourage them to actively participate in the treatment process, which will help promote the overall development of personalized medicine. 4.4 Future development trends With the continuous innovation of science and technology, genomic information will play an increasingly important role in optimizing drug treatment and personalized medicine. Looking into the future, it is expected that genomic information will promote the development of precision drugs. By in-depth understanding of the molecular mechanisms of diseases, precision drugs can be developed that target specific genetic variations to improve treatment effects and reduce side effects. Genomic information will also assist preventive medicine, improving patient health by predicting disease risk and enabling early intervention and preventive treatment. In terms of personalized treatment, genomic information will help doctors develop treatment plans that are more in line with the patient's individual characteristics (Sarvan and Nori, 2021). By analyzing a patient's genomic information, doctors can predict the patient's response to drugs and adjust drug dosage, combinations or treatment strategies to achieve truly personalized treatment. In the future, the application of genomic information will not only be limited to the field of genomics, but will also be deeply integrated with other disciplines such as medicine, bioinformatics, and computer science to promote interdisciplinary cooperation and technological innovation. This will accelerate the development of personalized medicine, promote progress in the medical field, and bring better treatment effects and quality of life to more patients. References CBarton J.C., Edwards C.Q., and Acton R.T., 2015, HFE gene: Structure, function, mutations, and associated iron abnormalities, Gene, 574(2): 179-192. https://doi.org/10.1016/j.gene.2015.10.009 PMid:26456104 PMCid:PMC6660136 Blobel B., Lopez D.M., and Gonzalez C., 2016, Patient privacy and security concerns on big data for personalized medicine, Health and Technology, 6: 75-81. https://doi.org/10.1007/s12553-016-0127-5 Foy S.P., Jacoby K., Bota D.A., Hunter T., Pan Z., Stawiski E., Ma Y., Lu W., Peng S., Wang C.L., Yuen B., Dalmas O., Heeringa K., Sennino B., Conroy A., Bethune M.T., Mende I., White W., Kukreja M., Gunturu S., Humphrey E., Hussaini A., An D., Litterman A.J., Quach B.B., Ng A.H.C., Lu Y., Smith C., Campbell K.M., Anaya D., Skrdlant L., Huang E.Y., Mendoza V., Mathur J., Dengler L., Purandare B., Moot R., Yi M.C., Funke R., Sibley A., Stallings-Schmitt T., Oh D.Y., Chmielowski B., Abedi M., Yuan Y., Sosman J.A., Lee S.M., Schoenfeld A.J., Baltimore D., Heath J.R., Franzusoff A., Ribas A., Rao AV., and Mandl S.J., 2023, Non-viral precision T cell receptor replacement for personalized cell therapy, Nature, 615(7953): 687-696. https://doi.org/10.1038/s41586-022-05531-1 PMid:36356599 PMCid:PMC9768791 Giacomini K.M., Yee S.W., Mushiroda T., Weinshilboum R.M., Ratain M.J., and Kubo M., 2017, Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine, Nature Reviews Drug Discovery, 16(1): 70-70. https://doi.org/10.1038/nrd.2016.234
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==